Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Topical Administration of Sitagliptin Prevents Retinal Neurodegeneration in a Model of Glaucoma Induced by Dexamethasone

  • Bogdanov, Patricia|||0000-0003-0669-4958
  • Duarri, Anna|||0000-0003-4075-5478
  • Sabater, David|||0000-0001-8113-8594
  • Canz, María José
  • Isla-Magrané, Helena|||0000-0002-7203-3309
  • Ramos, Hugo|||0000-0001-6443-7576
  • Deàs Just, Anna|||0000-0002-3129-6313
  • Simó Canonge, Rafael|||0000-0003-0475-3096
  • Hernández, Cristina|||0000-0002-3109-1721
Glaucoma is a neurodegenerative disease characterized by progressive degeneration of optic nerve axons and loss of retinal ganglion cells (RGCs). Although elevated intraocular pressure (IOP) is a major risk factor, many patients develop glaucoma with normal IOP, highlighting the need for neuroprotective therapies. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, has shown beneficial effects in diabetes-induced retinal neurodegeneration. This study aimed to evaluate whether sitagliptin eye drops, previously effective in diabetes-induced retinal neurodegeneration, could prevent corticosteroid-induced glaucoma. Glaucoma was induced in mice by periocular injection of dexamethasone (DEX) once weekly for five weeks. Sitagliptin or vehicle eye drops were administered from day 14 to 35. Untreated mice served as controls. DEX treatment caused significant loss of RGC bodies and optic nerve axons compared to controls, which was prevented by sitagliptin eye drops (p. < 0.001), without affecting IOP. Sitagliptin also inhibited DEX-induced activation of macroglia and microglia and prevented oligodendrocyte loss. Furthermore, it suppressed overexpression of galectin-3 and gamma-synuclein in the optic nerve head (ONH) (p < 0.001), key mediators of inflammation and apoptosis. Sitagliptin eye drops exert a potent neuroprotective effect against corticosteroid-induced glaucoma, supporting their potential as a novel therapeutic strategy for glaucoma.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Topical Administration of Sitagliptin Prevents Retinal Neurodegeneration in a Model of Glaucoma Induced by Dexamethasone

  • Sabater Martínez, David
  • Canz, María José
  • Bogdanov, Patricia
  • Duarri, Anna
  • Isla-Magrané, Helena
  • Ramos Abellán, Hugo
  • Deàs-Just, Anna
  • Simó Canonge, Rafael
  • Hernandez, Cristina
Dexamethasone-induced experimental model; Dipeptidyl peptidase 4 inhibitors; Eye drops, Modelo experimental inducido por dexametasona; Inhibidores de la dipeptidil peptidasa 4; Gotas oftálmicas, Model experimental induït per dexametasona; Inhibidors de la dipeptidil peptidasa 4; Gotes oftàlmiques, Glaucoma is a neurodegenerative disease characterized by progressive degeneration of optic nerve axons and loss of retinal ganglion cells (RGCs). Although elevated intraocular pressure (IOP) is a major risk factor, many patients develop glaucoma with normal IOP, highlighting the need for neuroprotective therapies. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, has shown beneficial effects in diabetes-induced retinal neurodegeneration. This study aimed to evaluate whether sitagliptin eye drops, previously effective in diabetes-induced retinal neurodegeneration, could prevent corticosteroid-induced glaucoma. Glaucoma was induced in mice by periocular injection of dexamethasone (DEX) once weekly for five weeks. Sitagliptin or vehicle eye drops were administered from day 14 to 35. Untreated mice served as controls. DEX treatment caused significant loss of RGC bodies and optic nerve axons compared to controls, which was prevented by sitagliptin eye drops (p < 0.001), without affecting IOP. Sitagliptin also inhibited DEX-induced activation of macroglia and microglia and prevented oligodendrocyte loss. Furthermore, it suppressed overexpression of galectin-3 and gamma-synuclein in the optic nerve head (ONH) (p < 0.001), key mediators of inflammation and apoptosis. Sitagliptin eye drops exert a potent neuroprotective effect against corticosteroid-induced glaucoma, supporting their potential as a novel therapeutic strategy for glaucoma., This research was funded by the “Ministerio de Industria, Economía y Competitividad” PDC2021-121638-I00, PID2022-138544OB-I00 and Instituto Carlos III-FEDER (RD21_0002_0052; PI22/01747). A.D-J. is a recipient of a grant from the “Ministerio de Industria, Economía y Competitividad” (PRE2020-095747). H.R is a recipient of the Torres Quevedo program funded by the Ministerio de Ciencia, Innovación y Universidades and the Agencia Estatal de Investigación (grant number PTQ2023-013246).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Topical Administration of Sitagliptin Prevents Retinal Neurodegeneration in a Model of Glaucoma Induced by Dexamethasone

  • Sabater Martínez, David
  • Canz, María José
  • Bogdanov, Patricia
  • Duarri, Anna
  • Isla-Magrané, Helena
  • Ramos Abellán, Hugo
  • Deàs-Just, Anna
  • Simó Canonge, Rafael
  • Hernandez, Cristina
Dexamethasone-induced experimental model; Dipeptidyl peptidase 4 inhibitors; Eye drops, Modelo experimental inducido por dexametasona; Inhibidores de la dipeptidil peptidasa 4; Gotas oftálmicas, Model experimental induït per dexametasona; Inhibidors de la dipeptidil peptidasa 4; Gotes oftàlmiques, Glaucoma is a neurodegenerative disease characterized by progressive degeneration of optic nerve axons and loss of retinal ganglion cells (RGCs). Although elevated intraocular pressure (IOP) is a major risk factor, many patients develop glaucoma with normal IOP, highlighting the need for neuroprotective therapies. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, has shown beneficial effects in diabetes-induced retinal neurodegeneration. This study aimed to evaluate whether sitagliptin eye drops, previously effective in diabetes-induced retinal neurodegeneration, could prevent corticosteroid-induced glaucoma. Glaucoma was induced in mice by periocular injection of dexamethasone (DEX) once weekly for five weeks. Sitagliptin or vehicle eye drops were administered from day 14 to 35. Untreated mice served as controls. DEX treatment caused significant loss of RGC bodies and optic nerve axons compared to controls, which was prevented by sitagliptin eye drops (p < 0.001), without affecting IOP. Sitagliptin also inhibited DEX-induced activation of macroglia and microglia and prevented oligodendrocyte loss. Furthermore, it suppressed overexpression of galectin-3 and gamma-synuclein in the optic nerve head (ONH) (p < 0.001), key mediators of inflammation and apoptosis. Sitagliptin eye drops exert a potent neuroprotective effect against corticosteroid-induced glaucoma, supporting their potential as a novel therapeutic strategy for glaucoma., This research was funded by the “Ministerio de Industria, Economía y Competitividad” PDC2021-121638-I00, PID2022-138544OB-I00 and Instituto Carlos III-FEDER (RD21_0002_0052; PI22/01747). A.D-J. is a recipient of a grant from the “Ministerio de Industria, Economía y Competitividad” (PRE2020-095747). H.R is a recipient of the Torres Quevedo program funded by the Ministerio de Ciencia, Innovación y Universidades and the Agencia Estatal de Investigación (grant number PTQ2023-013246).